Switching from Biologic to Biosimilar: Australia’s Unique Approach

Switching patients from an originator biologic (the reference product) to a biosimilar version has been a topic of keen interest in recent years, both in Australia and globally, as more biosimilars have emerged onto the market. This trend has flowed from the expiration of data exclusivity and patent protection for a number of important originator

Patent news from Europe: the Unitary Patent and the Unified Patent Court move a step closer

On World IP Day (26 April 2018), it was announced that the UK has ratified the Unified Patent Court Agreement (UPC Agreement).  Now only ratification by Germany is needed for the legislation to come into force.   What is the Unitary Patent? Currently, when a European patent application is granted, it essentially becomes a “bundle”